GOP Sens. Graham and Sasse praise Biden’s purchase of 500M Pfizer vaccines to share globally

Sens. Lindsey Graham (R-S.C.) and Ben Sasse (R-Neb.) on Thursday praised the Biden administration’s choice to purchase 500 million doses of the Pfizer coronavirus vaccine to share with nations world wide, calling the choice the “right move.”

The huge image: Their statements symbolize a uncommon second of praise of Biden by Republicans.

Get market information worthy of your time with Axios Markets. Subscribe for free.

  • Sasse has advocated for the U.S. to distribute 1 billion vaccines worldwide by Thanksgiving, and in a earlier statement referred to as the Biden administration’s world vaccination plans “timid.”

What they’re saying: “Health diplomacy is a smart investment and buying these vaccines is the right move. America should have an aggressive strategy to vaccinate a billion people around the world this year,” Sasse said in a statement.

  • “America should administer these vaccines directly in order to counter the Chinese Communist Party’s strategy of using the pandemic to gain the upper hand.”

  • “We should move quickly to share these life-saving shots with friends in Asia and across the developing world with a simple message: Uncle Sam, not Chairman Xi, cares about your health.”

Graham stated in a statement that the “roughly $3.5 billion required to purchase and distribute 500 million doses of vaccine will help prevent a reemergence of the COVID-19 virus which makes America and the world safer.”

  • “I assist the trouble of the Biden Administration to donate vaccines to at-risk populations all through the world and hope different nations will comply with America’s lead. I imagine this to be a great funding by the American taxpayer.

  • “Again, I do hope different nations will contribute their honest share. The sooner we have now vaccines accessible to the world, the higher,” Graham added.

Editor’s notice: This story has been up to date with Graham’s assertion.

Like this text? Get extra from Axios and subscribe to Axios Markets for free.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *